788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58

Current guidelines recommend prescribing SGLT2 inhibitors to patients (pts) with type 2 diabetes (T2D) and established or at high risk for cardiovascular (CV) disease, irrespective of HbA1c levels. We assessed whether the CV and renal benefits of dapagliflozin vary by baseline HbA1c. In the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 study 17160 pts with T2D were randomized to dapagliflozin (DAPA) or placebo (PBO) for a median follow up of 4.2 years. Baseline HbA1c was 0.05, figure). In a pre-specified subgroup analysis, high HbA1c levels posed greater CV and renal risk, yet the benefits of DAPA were observed irrespective of baseline HbA1c including those with HbA1c Disclosure A. Cahn: Advisory Panel; Self; AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Eli Lilly and Company, Novo Nordisk, Consultant; Self; Glucome, Medial Early Sign, Speaker’s Bureau; Self; AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk. I. A. Gause-nilsson: Employee; Self; AstraZeneca. A. Langkilde: Employee; Self; AstraZeneca, Stock/Shareholder; Self; AstraZeneca. M. S. Sabatine: Consultant; Self; Althera, Amgen Inc., Anthos Therapeutics, AstraZeneca, Bristol-Myers Squibb Company, Intarcia Therapeutics, Inc., Merck & Co., Inc., Research Support; Self; Amgen Inc., Anthos Therapeutics, AstraZeneca, Daiichi Sankyo, Eisai Inc., Intarcia Therapeutics, Inc., Medicines Company , MedImmune, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. I. Raz: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi, Consultant; Self; AstraZeneca, BOL, Camereyes, Concenter BioPharma Ltd., DarioHealth, Diabot, Exscopia, GlucoMe, Insuline Medical, Medial EarlySIgn, Orgenesis Inc., Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi, Stock/Shareholder; Self; BOL, Camereyes, DarioHealth, Diabot, GlucoMe, Orgenesis Inc. S. D. Wiviott: Consultant; Self; Aegerion Pharmaceuticals Inc., Allergan, AngelMed, Arena Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Boston Clinical Research Institute, LLC., Bristol-Myers Squibb Company, Daiichi Sankyo, Eisai Inc., Eli Lilly and Company, ICON Clinical, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Servier, St. Jude Medical, Xoma, Employee; Spouse/Partner; Merck & Co., Inc., Research Support; Self; Amgen Inc., Arena Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Daiichi Sankyo, Eisai Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Sanofi-Aventis. O. Mosenzon: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., BOL Pharma, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Sanofi. S. Murphy: Research Support; Self; Abbott, Amgen Inc., Anthos, AstraZeneca, Daiichi Sankyo, Eisai Co., Ltd., Intarcia Therapeutics, Inc., MedImmune, LLC, Merck & Co., Inc., Novartis AG. E. L. Goodrich: Research Support; Self; AstraZeneca. D. L. Bhatt: Research Support; Self; Afimmune Limited, Amarin Corporation plc, Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Idorsia Pharmaceuticals Ltd, Lexicon Pharmaceuticals, Inc., PLx Pharma Inc., Sanofi-Aventis. L. A. Leiter: Advisory Panel; Self; Abbott Diabetes, Amgen Inc., AstraZeneca, Bayer Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Esperion, Janssen Pharmaceuticals, Inc., Funding AstraZeneca